Improved Method for LSD Production and Novel Derivatives

The European Patent Office published patent application EP4178956A2 for MiHKAL GmbH on April 1, 2026, covering an improved method for producing lysergic acid diethylamide (LSD) and novel derivatives thereof. The patent application, filed under IPC classification C07D (heterocyclic compounds), designates 31 European contracting states including Germany, France, and the United Kingdom.

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

The European Patent Office published patent application EP4225447A1 for Vertex Pharmaceuticals Incorporated, covering CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds. The application was published April 1, 2026 with IPC classifications in pharmaceutical compositions (A61P 43/00, A61K 31/519) and specific chemical compounds (C07D 515/04). The patent lists 24 named inventors and designates all EPO contracting states.

Fluoropyrimidine Compound and Fluoropyrimidinone Compound

The European Patent Office granted Patent EP4155299A1 to Unimatec Co., Ltd. for fluoropyrimidine and fluoropyrimidinone compounds. The patent, classified under IPC C07D 401/04 (heterocyclic compounds), provides Unimatec with exclusive rights to these chemical compounds across 34 designated contracting states. Inventors include AOTSU Rie, SEINO Junya, and KOKIN Keisuke.

Foghorn BAF Complex Modulators Patent Application

The European Patent Office published patent application EP4096667A1 filed by Foghorn Therapeutics Inc., covering heterocyclic BAF complex modulators for therapeutic use. The application includes claims for compounds classified under multiple C07D subgroups and A61K preparations, with anticancer (A61P 35/00) as the stated therapeutic indication. The patent designates all 44 EPO contracting states covering compositions and methods of treatment.

Compounds and Compositions as Modulators of TLR Signaling

The European Patent Office published Patent EP4217342A1 granting Neuropore Therapies, Inc. exclusive rights to novel TLR signaling modulator compounds and compositions. The patent covers small molecule modulators with potential therapeutic applications for neurological conditions including Alzheimer's disease. Protection extends across 28 designated European contracting states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Compositions and Methods for Treatment and Prevention of Neurological Disorders

The European Patent Office published patent EP4165025A2 granted to Yumanity Therapeutics, Inc. covering compositions and methods for treating neurological disorders. The patent claims cover specific chemical compounds classified under A61K 31/5377 and A61K 31/519 with applications for neurological conditions including A61P 25/28. The patent is validated in designated European member states including Germany, France, United Kingdom, Italy, and Spain.

Boston Scientific left atrial appendage implant, published 1st Apr

Boston Scientific left atrial appendage implant, published 1st Apr

Cochlear implant drug delivery system, EP3684456A2

The European Patent Office published patent application EP3684456A2 by Cochlear Limited for an implantable therapeutic substance delivery system designed for cochlear implants. The system enables localized delivery of therapeutic substances to the inner ear through an implanted device. The application covers designated states across the European Economic Area.

Ophthalmic System Including Accommodating Intraocular Lens and Remote Component

The European Patent Office published patent EP3876868A1 for Verily Life Sciences LLC covering an ophthalmic system with an accommodating intraocular lens and remote component. The patent was published on April 1, 2026, with A61F 2/16 classification. The patent grants intellectual property protection across 31 EPO designated member states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Release Therapeutics SA Sustained-Release Implant Capsule

The European Patent Office granted patent EP4013381A1 to Release Therapeutics SA, Les Hôpitaux Universitaires de Genève, and Université de Genève for an implantable capsule designed for sustained-release drug delivery. The invention covers the capsule structure and composition with applications in medical treatment delivery.